SYSTEMATIC REVIEW

Sexual transmission of Hepatitis C Virus infection in a heterosexual population: A systematic review [version 1; referees: 2 approved]

Francesca Wuytack, Vittoria Lutje, Janus Christian Jakobsen, Karl Heinz Weiss, Paula Flanagan, Georgina Gethin, Louise Murphy, Siobhan Smyth, Declan Devane, Valerie Smith

1School of Nursing & Midwifery, Trinity College Dublin, Dublin, D02 T283, Ireland
2Cochrane Infectious Diseases Group, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK
3Rigshospitalet Copenhagen, Copenhagen Trial Unit, Copenhagen O, DK-2100, Denmark
4Internal Medicine IV, Head of Section of Transplant Hepatology, Liver Cancer Center Heidelberg, Heidelberg, Germany
5Health Services Executive Health Protection Surveillance Centre, Dublin, D01 A4A3, Ireland
6School of Nursing & Midwifery, National University of Ireland Galway, Galway, Ireland

Abstract

Background: Hepatitis C virus (HCV) infection is an important cause of liver disease worldwide. Identification of risk factors can guide screening and prevention. Sexual transmission in monogamous heterosexual relationships is rare but it is uncertain which sexual behaviours are linked to HCV transmission. This review aimed to determine risk factors for sexual HCV transmission in heterosexuals in low HCV prevalence countries (PROSPERO registration CRD42016051099).

Methods: We searched Medline, Embase, Science Citation Index-Expanded, Social Sciences Citation index, Conference proceedings (Web of Science), CINAHL, Scopus, LILACS, PubMed, and grey literature (04/11/2016). We included studies published in/after the year 2000 that examined sexual risk factors for HCV infection, other than interspousal transmission, in heterosexual adults (≥18 years). We excluded prisoners, people who inject drugs (PWIDs), people co-infected with HIV or from high prevalence countries. Two reviewers completed study selection, data extraction, risk of bias and quality of evidence assessment (GRADE) independently. Meta-analysis could not be conducted.

Results: Eight studies were included, examining seven factors (multiple sex partners, receiving/providing sex commercially, PWID partner, and unprotected vaginal, oral, anal sex). None were significant, except the evidence for the factor having a PWID partner was conflicting.

Conclusions: We are uncertain about the results due to the very low quality of evidence (GRADE). A more liberal approach to review inclusion criteria might be useful in further identifying factors associated with an increased risk of sexual transmission of HCV infection in a heterosexual population. However, caution should be applied to avoid the impact of confounders on the findings.
Keywords
hepatitis C virus, viral hepatitis, public health policy, risk factors, sexual transmission, systematic review

Corresponding author: Francesca Wuytack (wuytacf@tcd.ie)

Author roles: Wuytack F: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; Lutje V: Investigation, Writing – Review & Editing; Jakobsen JC: Investigation, Writing – Review & Editing; Weiss KH: Investigation, Writing – Review & Editing; Flanagan P: Conceptualization, Investigation, Writing – Review & Editing; Gethin G: Investigation, Writing – Review & Editing; Murphy L: Investigation, Writing – Review & Editing; Smyth S: Investigation, Writing – Review & Editing; Devane D: Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Supervision, Writing – Review & Editing; Smith V: Formal Analysis, Funding Acquisition, Investigation, Methodology, Writing – Review & Editing

Competing interests: The National University of Ireland Galway received payment for the conduct of this research from the National Clinical Effectiveness Committee of the Department of Health (Ireland) who commissioned this work. VL’s institution received payment from the National University of Ireland Galway to conduct the search for this review.

Grant information: This work was supported by the Clinical Effectiveness Unit of the Department of Health (Ireland). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Wuytack F et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Wuytack F, Lutje V, Jakobsen JC et al. Sexual transmission of Hepatitis C Virus infection in a heterosexual population: A systematic review [version 1; referees: 2 approved] HRB Open Research 2018, 1:10 (https://doi.org/10.12688/hrbopenres.12791.1)

First published: 08 Mar 2018, 1:10 (https://doi.org/10.12688/hrbopenres.12791.1)
Introduction

Hepatitis C virus (HCV) infection was first identified in 1989. Chronic HCV infection is an important cause of chronic liver disease and liver related death worldwide with an estimated 130 to 150 million persons having chronic HCV infection globally. The prevalence of HCV infection varies across countries and areas. Of those infected with HCV, many are asymptomatic with approximately 20% to 30% developing acute symptoms and 55% to 85% developing chronic infection. Of those who develop chronic infection, 15% to 30% will develop liver cirrhosis within 20 years. Annually, approximately 3% to 4% of patients with liver cirrhosis develop hepatocellular carcinoma.

Identification of risk factors associated with HCV transmission is essential in guiding screening and prevention strategies to improve health outcomes and maximise cost-effectiveness. There is currently no effective vaccination for HCV, putting even more emphasis on infection prevention. Since the introduction of routine screening of blood in the early 1990s, transfusion-related HCV infection is rare. Literature on risk factors for HCV infection indicate that Injecting Drug Use (IDU) is now the main mode of transmission. Other reported risk factors include occupational exposure, tattooing or having blood transfusions, vertical transmission and sex with an infected partner.

The role of sexual transmission in HCV transmission is not fully understood and an increasing number of studies examine this question. Some studies found HCV RNA in semen, but other studies have contradicted these findings. Tohme and Holmberg conducted a systematic review concerning the risk of HCV sexual transmission. They found that having multiple sexual partners might increase risk of HCV infection, although this finding may be confounded by IDU. Moreover, HIV co-infected individuals and Men who have Sex with Men (MSM) were clearly more at risk. Sexual transmission in people in monogamous heterosexual relationships on the other hand is rare; however, it is uncertain what specific sexual behaviours in heterosexuals do increase the risk of HCV transmission. Since their review was published in 2010, additional studies have emerged and an updated review was required to inform guidance on screening for HCV infection. We also aimed to increase generalisability to the context of low HCV prevalence countries because in high endemic countries there may be other risk factors in the population that make it difficult to identify sexual transmission at the source. Moreover, we focussed on heterosexuals but excluded high risk populations such as people who inject drugs (PWID), prisoners and HIV co-infected people, to address the question of when HCV screening is warranted in a more general population. Subsequently, the aim of this systematic review was to determine what factors, if any, are associated with an increased risk of sexual transmission of HCV infection in a heterosexual population in low HCV prevalence countries. This review was registered in PROSPERO (CRD42016051099).

Methods

Search strategy

A comprehensive search of both electronic databases and grey literature was conducted by VL. We searched the following databases up to 4th November 2016, attempting to identify all relevant studies: Medline (OVID), EMBASE (OVID), Science Citation Index-Expanded, Social Sciences Citation index, Conference proceedings (Web of Science), Cinahl (EBSCO-Host), Scopus and LILACS (Bireme). We used a combination of controlled vocabulary terms and free-text terms including: Hepatitis C, Hepacivirus, Incidence, Prevalence, Risk-Taking, Risk Factors, Sexually Transmitted Diseases, transmission, Exposure, Sexual Behavior, Sexual Partners. We adapted the queries to each database. We did not limit our searches by time or language. We searched for additional studies by reviewing the reference lists of all included studies, and by using the “Similar articles” function in Medline. For grey literature, we looked at the following websites: WHO (World Health Organization); CDC (Centre for Disease Control and Prevention); ECDC (European Centre for Disease Control and Prevention); BASHH (British Association for Sexual Health & HIV); IUSTI (International Union against Sexually Transmitted Infections); AASLD (American Association for the Study of Liver Diseases); EASL (European Association for the Study of the Liver); Society for the Study of Sexually Transmitted Diseases in Ireland (SSSTDI); American Sexually Transmitted Diseases Association (ASTDA).

More details on the search terms can be found in Figure 1.

Selection criteria

The selection criteria were set in Population, Exposure, Outcome, Study design (PEOS) format. The population of interest included heterosexual adults (≥ 18 years), excluding those with HIV co-infection, PWIDs, homo- or bisexuals, or prisoners, because these populations are at high risk of HCV infection. In addition, this review excluded studies conducted in high HCV prevalence countries, because the aim of this review was to provide guidance for assessing the need of screening specific populations in the setting of low HCV prevalence countries. The list of high HCV prevalence countries was obtained from the Health Protection Surveillance Centre (Ireland), Infectious disease assessment for migrants, but the HCV prevalence of Nigeria was changed to high (≥ 3%) following the publication of the epidemiological report on hepatitis C and B by the European Centre for Disease Prevention and Control in August 2016.

The exposure was any sexual behaviour factor including (but not limited to) having multiple sex partners, overlapping (more than one sexual relationship at the same time), changing sexual partners frequently, unprotected sex outside of monogamous relationship (sex acts without the use of a condom), exchange of sex for drugs (but not PWID) or money, being a commercial sex worker, sex with commercial sex workers, sex under the influence of drugs or alcohol, anal sex, having another Sexual Transmitted Infection (STI) (excluding HIV), having a high risk partner (defined as any of the above). The exposure could be self-reported or based on an objective measure e.g. the number of occasions condoms used/not used. The outcome HCV infection had to be determined by antibody/antigen or PCR RNA test, excluding self-reported HCV status.

We included cohort studies, case-control studies and cross-sectional studies, but excluded case studies, case series and reviews. We only included studies published in or after the year 2007.
Figure 1 - Search terms used in electronic databases

MEDLINE (Ovid):

1. ("Hepatitis C" or "hep C" or HCV†).ab. or ("Hepatitis C" or "hep C" or HCV†).ti. or Hepatitis C, Chronic/ or Hepatitis C/ or Hepacivirus/ and (Incidence/ or Prevalence/ or Epidemiology/ or Risk-Taking/ or Risk Factors/ or Sexually Transmitted Diseases/tm [Transmission] or (Transmission or transmitted or exposure or exposed or prevalence or incidence or risk or distribution or behavior† or factor†).ab. or (Transmission or transmitted or exposure or exposed or prevalence or incidence or risk or distribution or behavior† or factor†).ti. and (Sexual Behavior/ or Sexual Partners/ or (Sex† or "sexual partner" or heterosexual† or "sexual relationship" or "sexual contact" or spouse† or "sex work" or prostitut† or monogamous or unprotected or promiscuous) or "high risk partner†").ab. or (Sex† or "sexual partner" or heterosexual† or "sexual relationship" or "sexual contact" or spouse† or "sex work" or prostitut† or monogamous or unprotected or promiscuous) or "high risk partner†")

EMBASE (Ovid):

("Hepatitis C" or "hep C" or HCV†).ab. or ("Hepatitis C" or "hep C" or HCV†).ti. or Hepatitis C, Chronic/ or Hepatitis C/ or Hepacivirus/ and (Incidence/ or Prevalence/ or Epidemiology/ or Risk-Taking/ or Risk Factors/ or (Transmission or transmitted or exposure or exposed or prevalence or incidence or risk or distribution or behavior† or factor†).ab. or (Transmission or transmitted or exposure or exposed or prevalence or incidence or risk or distribution or behavior† or factor†).ti. and (Sexual Behavior/ or Sexual Partners/ or (Sex† or "sexual partner" or heterosexual† or "sexual relationship" or "sexual contact" or spouse† or "sex work" or prostitut† or monogamous or unprotected or promiscuous) or "high risk partner†").ab. or (Sex† or "sexual partner" or heterosexual† or "sexual relationship" or "sexual contact" or spouse† or "sex work" or prostitut† or monogamous or unprotected or promiscuous) or "high risk partner†")

Web of Science Core Collection

((TOPIC: ("hepatitis C" OR HCV) AND TOPIC: (((incidence OR prevalence) OR transmission) OR exposure) OR risk)) AND TOPIC: (((((((Sex† or "sexual partner" or heterosexual† or "sexual relationship" or "sexual contact" or spouse† or "sex work" or prostitut† or monogamous or unprotected or promiscuous) OR "high risk partner†"))))

CINAHL (EBSCOHost)

TI (hepatitis c or hcv) OR AB (hepatitis c or hcv) OR MH hepatitis c and (MH (incidence or prevalence or epidemiology) OR MH risk factors OR MH risk taking OR TI Transmission or transmitted or exposure or exposed or prevalence or incidence or risk or distribution or behaviour† or factor†) OR AB Transmission or transmitted or exposure or exposed or prevalence or incidence or risk or distribution or behaviour† or factor† and (MH sexual behaviour OR MH sexual partners OR TI (Sex† or "sexual partner" or heterosexual† or "sexual relationship" or "sexual contact" or spouse† or "sex work" or prostitut† or monogamous or unprotected or promiscuous) or "high risk partner†") OR AB (Sex† or "sexual partner" or heterosexual† or "sexual relationship" or "sexual contact" or spouse† or "sex work" or prostitut† or monogamous or unprotected or promiscuous) or "high risk partner†")

SCOPUS

(TITLE-ABS-KEY("hepatitis c" or hcv) AND TITLE-ABS-KEY(transmission or exposure or prevalence or incidence or risk) AND TITLE-ABS-KEY(Sex† or "sexual partner" or heterosexual† or "sexual relationship" or "sexual contact" or spouse† or "sex work" or prostitut† or monogamous or unprotected or promiscuous) or "high risk partner†") AND SUBJAREA(MULT OR AGRI OR BIOC OR IMMU OR NEUR OR PHAR OR MULT OR MEDI OR NURS OR VETE OR DENT OR HEAL) AND (LIMIT-TO(DOCTYPE,"ar") OR LIMIT-TO(DOCTYPE,"re") OR LIMIT-TO(DOCTYPE,"cp") OR LIMIT-TO(DOCTYPE,"le") OR LIMIT-TO(SUBJAREA,"MEDI")

LILACS (Bireme)

"hepatitis C" OR HCV [Words] and transmission or risk or exposure [Words] and sex$ or partner$ or heterosexual or spouse$ or monogamous or prostitut$ [Words]

Figure 1. Search terms used in electronic databases.
2000 because of the variability in the quality of HCV serological testing in earlier studies.

**Study selection**

Records identified in the search were screened independently by title/abstract and then by full-text by at least two reviewers (FW, VS, PF, GG, LM, SS). Conflicts were resolved by FW, VS and PF through discussion, and if necessary by involving another reviewer (DD).

**Data extraction and risk of bias assessment**

Risk of bias (ROB) in the included studies was assessed by two independent reviewers (FW, JCI) using the Quality In Prognosis Studies (QUIPS) tool\(^1\)\(^9\). The ROB criteria for each QUIPS domain specific to this review, including appropriate methods for HCV infection measurement and important confounders should have been adjusted for, were documents a priori and agreed by all authors. Conflicts were resolved through discussion. A data extraction form was developed and reviewed by all authors. Data extraction was conducted by two reviewers independently (VS, GG, LM and FW). Any conflicts were resolved by a third reviewer (FW).

**Data analysis**

When only raw data (proportions) were available, we calculated the unadjusted Odds Ratios (OR) and 95% Confidence Intervals (CI) using the natural log scale\(^1\)\(^9\). We planned to conduct meta-analyses in Revman\(^2\)\(^9\) and to assess statistical heterogeneity (F ≥ 50%, T ≥ 0, or the p-value > 0.10 for the Chi square test)\(^2\)\(^9\). However, it was not appropriate to carry out meta-analysis due to clinical and methodological heterogeneity, and findings are summarised narratively and presented in evidence tables.

The quality of evidence was assessed by two independent reviewers (VS and FW) using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for prognostic factor research\(^2\)\(^0\). This review was reported according to the Meta-analysis of observational studies in epidemiology (MOOSE) guidelines (completed checklist in Supplementary File 1)\(^2\)\(^1\).

**Results**

A total of 10460 records were identified through the database searches. We did not identify any records through the grey literature searches. Two further duplicates were detected and 10458 records were screened by title and abstract, of which 274 were selected as potentially eligible and assessed by full-text. A total of eight studies were finally included.

We contacted the authors to obtain more information to assess eligibility for an additional 11 records in abstract format and these are awaiting classification. Full details of the search results and selection process are presented in Figure 2.

**Characteristics of included studies**

The 8 included studies were published between the year 2000 and 2015, in Mexico (n=2), USA (n=2), Vietnam (n=1), Scotland (n=1), Gambia (n=1), and Brazil (n=1). A total of 14036 participants were included in the eight studies and seven potential sexual risk factors were assessed across the studies. These were multiple sex partners, receiving or providing sex commercially, having a PWID (People who inject drugs) partner, and unprotected vaginal, oral or anal sex.

Only three factors were examined in more than one study. The majority of studies included sample populations from specific groups; one study examined risk factors in a sample of blood donors\(^2\)\(^4\), one involved pregnant women attending antenatal services\(^2\)\(^5\), one in homeless people\(^2\)\(^6\), one in non-PWIDs\(^2\)\(^7\), one in nurses\(^2\)\(^8\), and one in a sample of different risk groups\(^2\)\(^9\). Full details of the characteristics of the included studies are presented in Table 1.

**Characteristics of excluded studies**

A total of 266 studies were excluded at full-text selection. Reasons for exclusion included participants under the age of 18 in the sample (n=38), study examined the prevalence of HCV but did not assess risk factors (n=31), and study publication not available in English (n=24), which may have introduced language bias. Many studies examined risk factors other than sexual factors of interest (n=25). Twenty-eight were excluded because of their study design; 24 were narrative reviews, three were systematic reviews, and one study was a case report. Sixty-seven studies included PWIDs, homosexuals and/or (ex-) prisoners in their sample and did not report findings separately for these groups.

**Risk of bias of included studies.**

Details of the judgment of ROB of each domain for each study are provided in Table 2. Study participation was judged as moderate (n=2) or high (n=6) ROB for all studies. Participants of included studies were specific groups that might have influenced the findings, such as healthy blood donor (n=1), nurses (n=1), pregnant women (n=1), homeless people (n=1). One study had a low recruitment rate\(^2\)\(^0\), but other studies did not describe their recruitment rate.

Seven of the 8 included studies were cross-sectional studies, hence there was low attrition bias. Only Neaigus et al.\(^2\)\(^7\) followed up patients and had a low retention rate of only 62.2%, leading to high risk of attrition bias. Six of the 8 studies were judged as low ROB for the domain risk factor measurement as the risk factor was measured using a structure questionnaire. Two studies were of moderate ROB because they did not provide a clear description of risk factor measurement.

All studies appropriately assessed the outcome HCV infection, most commonly using the ELISA kit, and were thus judged as low ROB. Four studies did not adjust for confounders and were therefore judged as high ROB for this domain. Nyamathi et al.\(^2\)\(^6\) adjusted for confounders but did not include some important confounders such as a history of tattooing and was judged as moderate ROB. The remaining three studies were judged low ROB. Four studies did not conduct multivariable analysis to adjust for confounders and hence were rated as high ROB for statistical analysis. Nyamathi et al.\(^2\)\(^6\) adjusted for some confounders (gender, age, age started living on their own, daily alcohol use) but not all important ones (e.g. tattooing/body piercing) were included in the model; hence this study was rated as moderate ROB.
10460 records identified through database searching:
- CINALH (n=50)
- Embase (n=3344)
- LILACS (n=97)
- Medline Ovid (n=4596)
- Scopus (n=1334)
- Web of Science (n=1000)
- Pubmed (n=39)

10458 records after duplicates removed

10458 of records screened
266 full-text articles excluded, with reasons:
- Further duplicates (n=9)
- Examined prevalence only (n=31)
- Includes participants aged < 18 years (n=38)
- Not in English (n=24)
- Narrative review/commentary/editorial (n=24)
- Systematic reviews (n=3)
- Case report (n=1)
- No sexual behaviours examined as potential risk factor (n=25)
- Co-infection with HIV or Hepatitis B (n=5)
- The outcome was 'any STI' (n=7)
- Examined inter-spousal transmission (n=4)
- Composite exposure factor of high risk sexual behaviour that includes MSM (n=8)
- Conducted in a high prevalent country (n=6)
- Includes IDUs (n=53)
- Includes homo- or bisexuals (n=3)
- Includes (ex-)prisoners (n=2)
- Includes IDUs and (ex-)prisoners (n=4)
- Includes IDU and homosexuals (n=5)
- Outcome is neighbourhood disorder (n=1)
- Awaiting classification; abstracts (n=11)
- The complete sample in HCV positive (no control) (n=1)
- Not retrievable (n=1)

10184 records excluded

274 full-text articles assessed for eligibility

8 studies included in qualitative synthesis

0 studies included in quantitative synthesis (meta-analysis)

Figure 2. Search and selection flow diagram.
<table>
<thead>
<tr>
<th>Study (Design)</th>
<th>Setting (Country)</th>
<th>Participant inclusion/exclusion criteria</th>
<th>Risk factors (measurement method)</th>
<th>Outcome measurement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dunford et al. (2012) (Cross-sectional)</td>
<td>Different geographic regions of Vietnam</td>
<td>8 different population groups including people who inject drugs (PWIDs), commercial sex workers (CSWs), blood donors, military recruits, pregnant women, dialysis patients, elective surgery patients and recipients of multiple blood transfusions.</td>
<td>Commercial sex worker (unclear)</td>
<td>Enzyme immunoassay (EIA) for HCV using the Monolisa Ag/Ab HCV Ultra (Bio-Rad Laboratories, CA, USA).</td>
</tr>
<tr>
<td>Goldberg et al. (2001) (Retrospective)</td>
<td>Ninewells Hospital Dundee, antenatal clinic (Scotland)</td>
<td>All women who were seen at the antenatal clinic and all women who were admitted for termination of pregnancy to the gynaecology wards.</td>
<td>Non-PWID but partner is PWID (Linked dataset information)</td>
<td>Initial screening by Ortho Diagnostics hepatitis C virus 3.0 ELISA Assay. If HCV antibodies identified, retested using Monolisa hepatitis C virus confirmatory testing; only serum samples which were reactive on both tests were considered to be HCV antibody positive.</td>
</tr>
<tr>
<td>Mboto et al. (2005) (Cross-sectional)</td>
<td>Royal Victoria Hospital, Banjul (Gambia)</td>
<td>Asymptomatic first-time blood donors.</td>
<td>Polygamous marriage</td>
<td>Polygamous marriage</td>
</tr>
<tr>
<td>Melo et al. (2015) (Cross-sectional)</td>
<td>Rural urban area – population 2,640 inhabitants (Brazil)</td>
<td>&gt; 18 years and providing informed consent for interview and blood sampling.</td>
<td>More than three sexual partners over a lifetime, &gt; 2 sexual partners over a lifetime (Structured interview questionnaire)</td>
<td>Enzyme immunoassay tests to detect the markers anti-HCV, Qualitative detection of hepatitis C virus-ribonucleic acid (HCV RNA [AmpliCor version 2.0, Roche]) was performed for the anti-HCV-positive serum or potentially positive serum.</td>
</tr>
<tr>
<td>Mendez-Sanches et al. (2005) (Cross-sectional)</td>
<td>University Hospital Check-up Unit, Mexico City (Mexico)</td>
<td>Inclusion: people with one of the following risk factors: blood transfusion before 1992; surgeries before 1992; IV drug use as unique risk factors. People with two or more of the following risk factors: tattoos, contact with known HCV-infected people; a previous manicure or pedicure with a non-personal instrument, dental surgery, more than three sexual partners.</td>
<td>Screening for HCV RNA, by qualitative polymerase chain reaction (PCR) using the Amplicor version 2.0 (Roche) was performed for the anti-HCV-positive serum or potentially positive serum.</td>
<td>HCV RNA Genotype Dupliyte Assay (Quest Diagnostics, USA).</td>
</tr>
<tr>
<td>Study (Design)</td>
<td>Setting (Country)</td>
<td>Participant inclusion/exclusion criteria</td>
<td>Risk factors (measurement method)</td>
<td>Outcome measurement</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
<td>----------------------------------------</td>
<td>----------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Mendez-Sanches et al. (2006)(^{a}) (Cross-sectional)</td>
<td>Tertiary-care hospital, Mexico City (Mexico)</td>
<td>All nursing personnel.</td>
<td>More than four sexual partners (Self-reported questionnaire)</td>
<td>Axsym HCV system version 3. In positive cases qualitative and quantitative viral load and genotype were assessed through PCR for RNA-HCV.</td>
</tr>
<tr>
<td>Neaigus et al. (2007)(^{a}) (Prospective longitudinal)</td>
<td>New York City (USA)</td>
<td>&gt;18 years, had used non-injected heroin during the preceding 30 days, and had either never injected drugs or had not done so during the preceding 6 months. Eligibility tests of urine, hair, body sites, structured screening questionnaire and ethnographic methods were used.</td>
<td>Unprotected vaginal sex, Unprotected anal sex, Unprotected oral sex, Commercial sex received, Commercial sex provided, Multiple sex partners in last 30 months, Sex with PWID (structured interview questionnaire)</td>
<td>HCV antibody tested by HCV EIA 2.0</td>
</tr>
<tr>
<td>Nyamathi et al. (2002)(^{a}) (Cross-sectional but sample derived from a quasi-experimental study)</td>
<td>36 homeless shelters or sober-living shelters or from street outreach in Los Angeles (USA)</td>
<td>18–65 years; homeless; having an intimate partner or friend termed an impoverished adult.</td>
<td>Multiple sex partners in last 6 months (No versus yes) (structured questionnaire)</td>
<td>Ortho HCV ELISA Test kit System Version 3.0</td>
</tr>
</tbody>
</table>

\(^{a}\)Includes some PWIDs but prevalence of non-PWIDs reported.

\(^{b}\)Even though PWIDs were not an exclusion criteria, no participants were PWIDs.
<table>
<thead>
<tr>
<th>Record</th>
<th>Study participation</th>
<th>Study attrition</th>
<th>Factor measurement</th>
<th>Outcome measurement</th>
<th>Study confounding</th>
<th>Statistical analysis and reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dunford et al. (2012)</td>
<td>+/-</td>
<td>-</td>
<td>+/-</td>
<td>Enzyme immerosassay (EIA) for HCV using the Monolisa Ag/Ab HCV Ulra (Bio-Rad Laboratories, CA, USA).</td>
<td>+</td>
<td>Multivariable analysis.</td>
</tr>
<tr>
<td>Goldberg et al. (2001)</td>
<td>+/-</td>
<td>-</td>
<td>-</td>
<td>Ortho Diagnostics hepatitis C virus 3.0 ELISA Assay (Chiron Corporation, Emeryville, California)</td>
<td>-</td>
<td>Multivariable analysis.</td>
</tr>
<tr>
<td>Mboto et al. (2005)</td>
<td>+</td>
<td>-</td>
<td>+/-</td>
<td>ELISA kit</td>
<td>-</td>
<td>Multivariable analysis.</td>
</tr>
<tr>
<td>Melo et al. (2015)</td>
<td>+/-</td>
<td>-</td>
<td>+/ -</td>
<td>virusribonucleic acid (HCV RNA) [Amplicor version 2.0 (Roche)] was performed for the anti-HCV-positive serum or potentially positive serum. Virusribonucleic acid (HCV RNA) [Amplicor version 2.0 (Roche)] was performed for the anti-HCV-positive serum or potentially positive serum.</td>
<td>-</td>
<td>Multivariable analysis.</td>
</tr>
<tr>
<td>Mendez-Sanches et al. (2005)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>Qualitative polymerase chain reaction (PCR) using the Cobas Amplicor HCV Test Version 2.0 (Roche Laboratories Ltd., USA). HCV RNA-positive serum was also screened by quantitative PCR using the Cobas Amplicor HCV Test Version 2.0 (Roche Laboratories Ltd.) with a dynamic range lower limit of 50 IU/mL. In HCV RNA-positive patients, genotyping was performed using the HCV RNA Genotype Duplitype Assay (Quest Diagnostics, USA), a DNA sequencing technology to subtype two regions of the HCV genome: the CORE gene and the NS5B region.</td>
<td>-</td>
<td>Multivariable analysis.</td>
</tr>
<tr>
<td>Record</td>
<td>Study participation</td>
<td>Study attrition</td>
<td>Factor measurement</td>
<td>Outcome measurement</td>
<td>Study confounding</td>
<td>Statistical analysis and reporting</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------</td>
<td>-----------------</td>
<td>--------------------</td>
<td>---------------------</td>
<td>------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>Mendez-Sanches et al. (2006)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Neaigus et al. (2007)</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Nyamathi et al. (2002)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+/-</td>
<td>+/-</td>
</tr>
</tbody>
</table>

*Risk of bias for each domain was judged as high (+), moderate (+/-) or low (-).*
Risk factors
A total of seven potential risk factors were examined in the eight included studies. Evidence for all factors was of very low quality and full details of the GRADE profiles by factor are provided in Table 3.

Six studies examined having had multiple sex partners as a potential risk factor for HCV infection (Table 4). Different cut-offs and analysis methods did not allow us to pool data in meta-analysis. Only one study adjusted for confounders and did not find having more than three sex partners in the last six months to be a significant risk factor. Similarly, the other five studies did not find a positive association. However, evidence should be interpreted with caution since the quality of evidence (GRADE) is very low.

Evidence of being a commercial sex worker as a risk factor for HCV infection was limited (measured in 2 studies only) and of very low quality (GRADE). Dunford et al. found that 8.7% of commercial sex workers were HCV positive, and of those 40.2% (n=87) were non-PWIDs, but did not report data on the comparison group (non-PWID CSWs negative for HCV). Neaigus et al. found a positive effect but it was not statistically significant (unadjusted OR 2.0 (0.6-6.7); p=0.3; n=277).

A history of having sex with a commercial sex worker was not associated with HCV infection (unadjusted OR 1.9 (0.5-8.0), p=0.4; Male: HR 4.1 (0.91–18.0); Female: not reported; n=277; one study), but the quality of evidence (GRADE) was very low due to only one study examining this factor with significant risk of bias.

### Table 3. GRADE profile of risk factors examined in included studies.

<table>
<thead>
<tr>
<th>Potential risk factor identified</th>
<th>No. of participants</th>
<th>Reference(s) &amp; phase of investigation</th>
<th>No. of studies</th>
<th>Univariate</th>
<th>Multivariate</th>
<th>GRADE factors</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>+ 0 - + 0 -</td>
<td>x v x e v v v +</td>
<td></td>
</tr>
<tr>
<td>Multiple sex partners</td>
<td>2884</td>
<td>Neaigus et al. (2007) (Phase 1)</td>
<td>6</td>
<td>0 6 0 1 0 1</td>
<td>x v x e v v v +</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nyamathi et al. (2002) (Phase 1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Melo et al. (2015) (Phase 1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mendez-Sanchez et al. (2005) (Phase 1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mendez-Sanchez et al. (2006) (Phase 1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mboto et al. (2005) (Phase 1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commercial sex work</td>
<td>7931</td>
<td>Dunford et al. (2012) (Phase 1)</td>
<td>2</td>
<td>0 2 0 0 0 1</td>
<td>x c x d v x e v v v +</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neaigus et al. (2007) (Phase 1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>History of sex with CSW</td>
<td>277</td>
<td>Neaigus et al. (2007) (Phase 1)</td>
<td>1</td>
<td>0 1 0 0 0 1</td>
<td>x c x d v x e v v v +</td>
<td></td>
</tr>
<tr>
<td>Partner who is an IDU</td>
<td>3775</td>
<td>Neaigus et al. (2007) (Phase 1)</td>
<td>2</td>
<td>1 1 0 0 0 1</td>
<td>x x c x d v x e v v v +</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Goldberg et al. (2001) (Phase 1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unprotected vaginal sex</td>
<td>277</td>
<td>Neaigus et al. (2007) (Phase 1)</td>
<td>1</td>
<td>0 1 0 0 0 1</td>
<td>x x c x d v x e v v v +</td>
<td></td>
</tr>
<tr>
<td>Unprotected anal sex</td>
<td>277</td>
<td>Neaigus et al. (2007) (Phase 1)</td>
<td>1</td>
<td>0 1 0 0 0 1</td>
<td>x x c x d v x e v v v +</td>
<td></td>
</tr>
<tr>
<td>Unprotected oral sex</td>
<td>277</td>
<td>Neaigus et al. (2007) (Phase 1)</td>
<td>1</td>
<td>0 1 0 0 0 1</td>
<td>x x c x d v x e v v v +</td>
<td></td>
</tr>
</tbody>
</table>

* Downgraded by one level because seven of the eight studies had at least one domain high ROB or two domains moderate ROB; ** Downgraded by one level because some studies have wide confidence intervals and no power calculations provided; *** Downgraded two levels since the study has more than 1 domain high ROB or two moderate; **** Downgraded by one level because the confidence intervals do not overlap; ***** Downgraded by one level because of a study has more than 1 domain high ROB or two moderate; **** Downgraded by one level because of the study has more than 1 domain high ROB or two moderate; ** For one of the two studies the effect could not be estimated and was subsequently classified as no effect; ** GRADE levels of evidence: + very low, ++ low, +++ moderate, ++++ high quality; Phase 1 of investigation (Hayden 2008), conducted only univariate analysis for the factor of interest; 1Phase of investigation (Hayden 2008), multivariable analysis but no specific hypotheses tested; Explanation of symbols: ‘+’ not downgraded/upgraded, ‘x’ downgraded/upgraded by one level, ‘xx’ downgraded/upgraded by two levels.
### Table 4. Multiple sex partners as a risk factor for Hepatitis C infection.

<table>
<thead>
<tr>
<th>Factor</th>
<th>Study</th>
<th>No of participants in analysis</th>
<th>Risk estimate (unadjusted)</th>
<th>Adjusted risk estimate</th>
<th>Confounders adjusted for</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple sex partners in the last 30 months</td>
<td>Neaigus et al. (2007)&lt;sup&gt;27&lt;/sup&gt;</td>
<td>277</td>
<td>OR&lt;sup&gt;a&lt;/sup&gt; 0.9 (0.4–2.1), p=0.8</td>
<td>/&lt;sup&gt;b&lt;/sup&gt;</td>
<td>N/A</td>
</tr>
<tr>
<td>&gt; 3 sex partners in last 6 months (No versus yes)</td>
<td>Nyamathi et al. (2002)&lt;sup&gt;31&lt;/sup&gt;</td>
<td>743 non-injection drug user samples</td>
<td>OR 0.2 (0.03 to 1.5)</td>
<td>AOR 0.14 (0.02 to 1.06)</td>
<td>Gender, age, ethnicity, age started living alone, recent daily alcohol use.</td>
</tr>
<tr>
<td>≥ 2 sexual partners over a lifetime</td>
<td>Melo et al. (2015)&lt;sup&gt;30&lt;/sup&gt;</td>
<td>1001</td>
<td>One (0.1%) case of confirmed HCV infection. This man denied blood transfusion. He reported no more than 5 sexual partners over a lifetime or 2 partners in the last 6 months.</td>
<td>/&lt;sup&gt;b&lt;/sup&gt;</td>
<td>N/A</td>
</tr>
<tr>
<td>&gt; 3 sexual partners</td>
<td>Mendez-Sanchez, et al. (2005)&lt;sup&gt;33&lt;/sup&gt;</td>
<td>300</td>
<td>OR&lt;sup&gt;a&lt;/sup&gt; 1.6 (0.3–8.1), p=0.6</td>
<td>/&lt;sup&gt;b&lt;/sup&gt;</td>
<td>N/A</td>
</tr>
<tr>
<td>&gt; 4 sexual partners</td>
<td>Mendez-Sanchez, et al. (2006)&lt;sup&gt;33&lt;/sup&gt;</td>
<td>376</td>
<td>OR&lt;sup&gt;a&lt;/sup&gt; 1.5 (0.08–29.7), p=0.8</td>
<td>Not included in multivariable analysis due to insignificant in univariate analysis.</td>
<td>N/A</td>
</tr>
<tr>
<td>≥ 6 sexual partners over a lifetime</td>
<td>Melo et al. (2015)&lt;sup&gt;30&lt;/sup&gt;</td>
<td>1001</td>
<td>One (0.1%) case of confirmed HCV infection. This man denied blood transfusion. He reported no more than 5 sexual partners over a lifetime or 2 partners in the last 6 months.</td>
<td>/&lt;sup&gt;b&lt;/sup&gt;</td>
<td>N/A</td>
</tr>
<tr>
<td>Polygamous marriage (vs monogamous marriage)</td>
<td>Mboto et al. (2005)&lt;sup&gt;34&lt;/sup&gt;</td>
<td>187</td>
<td>OR 2.6 (0.24–27.8)</td>
<td>/&lt;sup&gt;b&lt;/sup&gt;</td>
<td>N/A</td>
</tr>
</tbody>
</table>

<sup>a</sup>Calculated from raw data (95% CI calculated using natural logarithm method<sup>19</sup>.  
<sup>b</sup>Adjusted risk estimate not available.

There was conflicting evidence regarding the role of having a partner who is a PWID as a risk factor for HCV infection and quality of evidence was very low due to significant ROB and a limited number of studies examining this factor. Goldberg et al.<sup>25</sup> found that having a PWID partner was a significant risk factor (unadjusted OR 56.6 (18.5 -173.60), p<0.0001; n=3498), but Neaigus et al.<sup>27</sup> found no association (unadjusted OR 1.2 (0.3 –5.2); n=277).

In one study (n=277), unprotected vaginal sex (unadjusted OR 1.5 (0.8–2.7), p=0.2; Males: Hazard Ratio (HR) 0.75 (0.25–2.3); Females: HR 0.49 (0.11–2.3)), unprotected anal sex (unadjusted OR 0.8 (0.2–3.1), p=0.8; Females: HR 1.7 (0.22–12.8); Male: not reported), and unprotected oral sex (unadjusted OR 0.7 (0.4–1.3), 0.2; Females: HR 0.93 (0.21–12.8); Male: not reported) were not associated with HCV infection (very low quality evidence)<sup>27</sup>.

### Discussion

Seven potential sexual risk factors for HCV transmission in a heterosexual population were examined in eight studies, including multiple sex partners, receiving or providing sex commercially, having a PWID partner, and unprotected vaginal, oral or anal sex. None of these factors were statistically significant risk factors in the included studies; however, we are uncertain about these results due to the very low quality of evidence (GRADE). Moreover, these results might have been affected by a potential lack of statistical power and none of the studies provided sample/power calculations. Goldberg et al.<sup>23</sup> did find that having a sex partner who is a PWID was associated with an increased
risk of HCV infection resulting in conflicting evidence because
the other study examining this factor did not find a significant
association. Goldberg et al. was conducted in Scotland, which
might provide more geographically relevant information as this
is a similar context to Ireland and other European countries.
However, being a partner of a PWID could also expose people
to non-sexual HCV transmission and may have confounded this
finding.

Evidence for all factors examined in the included studies was
of very low quality, mainly due to a lack of replication and high
ROB resulting from a lack of adjusting for confounders and
selective samples. Incomplete or non-standardised measurement
of sex practices in some of the included studies could also have
impacted on the findings of this review. Moreover, only seven
factors were examined in the included studies and other factors
such as use of condom, sex during menses, rough sex, presence
of other STIs etc., were not measured and assessed. Even though
we excluded studies that examined PWIDs, subjects may not
disclose being a PWID, particularly since data on factors was
generally obtained through a self-reported questionnaire.

The strengths of this review lie in its comprehensive search,
its double independent study selection, ROB assessment, data
extraction and GRADE quality assessment.

This review adhered to the a priori selection criteria set and
excluded any study that included PWIDs, prisoners and/or
homo- or bisexuals in their sample in the absence of subgroup
analyses for these groups. This approach limited the number of
included studies. A more liberal approach to review study inclusion
criteria (i.e. including the 67 studies that partly included these
groups) might be useful in further addressing the objective of
this review. However, caution should be had when doing so to
avoid the impact of confounders on the findings and we would
recommend conducting subgroup analyses in such case.

Data availability
All data underlying the results are available as part of the article
and no additional source data are required.

Author contributions
FW and DD designed the protocol with input from all authors.
VL constructed and conducted the search. All authors reviewed
the search. FW, VS, PF, SS, LM, GG conducted study selection
and data extraction. FW and JCC conducted the ROB assess-
ment. FW and VS conducted the GRADE quality assessment.
FW drafted the manuscript. All authors were involved in the data
interpretation and reviewed the manuscript.

Competing interests
The National University of Ireland Galway received payment
for the conduct of this research from the National Clinical
Effectiveness Committee of the Department of Health (Ireland)
who commissioned this work.

VL’s institution received payment from the National University
of Ireland Galway to conduct the search for this review.

Grant information
This work was supported by the Clinical Effectiveness Unit of the
Department of Health (Ireland).

The funders had no role in study design, data collection and analy-
sis, decision to publish, or preparation of the manuscript.

Acknowledgements
We thank the Steering Group for this project for their insight and
support through the conduct of this work. We would like to thank
Dr Rania Tohme (Centers for Disease Control, Atlanta, USA) for
providing expert advice for this review.

Supplementary material
Supplementary File 1: MOOSE checklist.

Click here to access the data.

References

362-4. PubMed Abstract | Publisher Full Text

2095-100. PubMed Abstract | Publisher Full Text


104-18. PubMed Abstract | Publisher Full Text

organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp,

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text


Reference Source

PubMed Abstract | Publisher Full Text

Reference Source


Reference Source

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text | Free Full Text
Open Peer Review

Current Referee Status: ✔ ✔

Version 1

Referee Report 08 January 2019
https://doi.org/10.21956/hrbopenres.13851.r26294

F. DeWolfe Miller
John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA

I have a few brief comments that may / should be addressed. Given that this can be easily done, I recommend that the manuscript be accepted for indexing.

_____________________

Re: Introduction - second paragraph: regarding transmission, an additional reference should be included for iatrogenic transmission, a significant but often overlooked route of transmission and the major driver of the HCV epidemic in Egypt.

Re: the study is appropriately registered PROSPERO (CRD42016051099). A necessary study criterion.

Discussion: I do not think that “of other STIs etc.,” should be included in peer reviewed scientific literature. Just reword accordingly.

Discussion: should the authors include in the Discussion that no discordant monogamous studies were found? Or that had been previously reviewed?

In general, this is a thorough up to date systemic review (following conventional guidelines for systemic review) of the role of sexual transmission of HCV infection. The findings, i.e. the lack of evidence for sexual transmission in low HCV prevalence communities is consistent with current literature, the lack of consistent isolation of HCVRNA from human genital track fluids, and the lack of evidence of transmission in monogamous discordant couples over time. Until concrete evidence to the contrary emerges, HCV is a blood borne pathogen. Thank you for this opportunity for service to HRB Open Research.

Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes

Are sufficient details of the methods and analysis provided to allow replication by others?
Yes

Is the statistical analysis and its interpretation appropriate?
Yes

Are the conclusions drawn adequately supported by the results presented in the review?
Yes

**Competing Interests:** No competing interests were disclosed.

**Referee Expertise:** I am a Fellow in the American College of Epidemiology. A tenured full professor in the John A Burns School of Medicine. I have published significant studies on the epidemiology of HCV.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Referee Report 29 May 2018

https://doi.org/10.21956/hrbopenres.13851.r26246

Lisa Maher  
Kirby Institute for Infection and Immunity, UNSW Sydney, Sydney, NSW, Australia

This systematic review examined studies of sexual risk factors for HCV infection, other than interspousal transmission, in heterosexual adults. It excluded prisoners, people who inject drugs, people co-infected with HIV and people from high prevalence countries. Two reviewers completed study selection, data extraction, risk of bias and quality of evidence assessment (GRADE) independently. Meta-analysis was not conducted and the authors recommend that future studies use expanded inclusion criteria.

The manuscript is well written (note: the acronym PWID is plural) and organized, uses a standardised approach (MOOSE guidelines with checklist available), assesses ROB (QUIPS) and quality of evidence (GRADE).

Results are not surprising with 8 very low quality studies (7 cross-sectional) included and high ROB as a result of lack of adjustment for confounders and selective samples. Additional limitations include incomplete or non-standardised measurement of sex practices in some studies and the failure to measure or assess potentially important factors including condom use, sex involving blood and the presence of other STIs.

While the inclusion of groups such as people who inject drugs and gay and bisexual men in future reviews may increase the number and quality of studies, the impact of confounders is likely to be significant.

Are the rationale for, and objectives of, the Systematic Review clearly stated?  
Yes

Are sufficient details of the methods and analysis provided to allow replication by others?  
Yes

Is the statistical analysis and its interpretation appropriate?  
Yes

Are the conclusions drawn adequately supported by the results presented in the review?  
Yes

**Competing Interests:** No competing interests were disclosed.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.